Monte Rosa Therapeutics, Inc. (GLUE) Stock Forecast Nov. 6, 2026

Our AI scores Monte Rosa Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.

Monte Rosa Therapeutics, Inc. is a small-cap company with a market capitalization of $874M. It ranks number 47 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.

For GLUE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 10.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)

All daily signals →